Carbon Dots Emerge as Promising Nanoagents Against COVID-19, Showcasing Potential for Diagnostics and Therapeutics

July 26, 2026

MDPI Switzerland

Overview

This review explores the application of carbon dots (CDs) as nanoagents against COVID-19, highlighting their biocompatibility, tunable photoluminescence, and rich surface chemistry. CDs are being investigated for high-sensitivity biosensing, antiviral nanomaterials, and fluorescence-based detection methods due to their low detection limits. The article details how synthetic routes, precursor compounds, heteroatom doping, and surface functionalization influence their optical behavior and biological performance, indicating broad therapeutic and diagnostic potential.

In Depth

Key Findings

This review reveals that carbon dots (CDs) are emerging as highly promising nanoagents against COVID-19, leveraging their excellent biocompatibility, tunable photoluminescence properties, and versatile surface chemistry. CDs hold significant potential for a wide range of applications, from diagnostic tools to therapeutic candidates.

Technical / Clinical Details

CDs are carbon-based nanoparticles typically smaller than 10 nm in diameter, whose physicochemical properties are highly variable depending on the synthesis route, precursor materials, doped heteroatoms (e.g., N, S, P), and surface functional groups. This review specifically elaborates on the potential of CDs’ fluorescent properties for highly sensitive detection of COVID-19 viruses and fluorescence imaging of infected cells. For instance, reports indicate their efficacy as biosensors for viral antigens or antibodies with high sensitivity and low detection limits (at the pM level). Furthermore, CDs are suggested to possess direct antiviral activity by binding to viral particles and inhibiting their replication, leading to ongoing development as novel antiviral nanomaterials. By functionalizing CD surfaces with specific receptor-binding molecules, targeted delivery to virus-infected cells can also be achieved, indicating their role as drug delivery system (DDS) carriers.

Background & Context

The COVID-19 pandemic highlighted the urgent need for rapid, accurate diagnostic methods and effective therapeutic strategies. Conventional diagnostic and treatment approaches faced limitations, particularly regarding highly sensitive early diagnosis and the development of targeted therapies with fewer side effects. Nanotechnology, especially nanomaterials like CDs, offers innovative solutions to these challenges. The low production cost, high biocompatibility, and facile functionalization of CDs make them highly attractive as a new platform to address global health crises.

Strategic Significance & Outlook

While research on utilizing CDs as nanoagents for COVID-19 is still in its early stages, their multifaceted potential is considered very high for future applications. Key research areas moving forward include verifying safety and efficacy in clinical trials, establishing large-scale production techniques, and evaluating synergistic effects in combination therapies with other antiviral agents. Beyond COVID-19, CD-based diagnostic and therapeutic platforms could be developed for other viral and bacterial infections. This would strengthen preparedness for future pandemics and contribute to the improvement of public health globally, offering a versatile and scalable approach to infectious disease management.

Source: https://www.mdpi.com/2227-9717/14/14/2372

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.